Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The naïve B-cell receptor (BCR) specific for Human Papillomavirus (HPV) L1 conformational epitopes is a membrane-bound immunoglobulin complex that serves as the primary recognition site for prophylactic HPV vaccines (Schiller & Lowy, 2012, Nat Rev Microbiol). These receptors are expressed on the surface of antigen-inexperienced B cells and are characterized by their high affinity for the three-dimensional arrangement of the L1 major capsid protein, which is presented in a highly repetitive manner on virus-like particles (VLPs) (Buck et al., 2013, J Virol). Upon binding to these conformational epitopes, the BCR undergoes cross-linking, which initiates downstream signaling through the Ig-alpha and Ig-beta subunits, leading to B-cell activation and the formation of germinal centers (Lowy & Schiller, 2006, J Clin Invest). This process results in the production of potent neutralizing antibodies that prevent the virus from binding to the basement membrane or entering host keratinocytes (Day et al., 2010, Structure). Prophylactic vaccines like Gardasil and Cervarix leverage this interaction to induce long-term protective immunity against high-risk HPV types, such as 16 and 18, which are responsible for the majority of cervical cancers (Harper et al., 2004, Lancet). The specificity of the BCR for conformational rather than linear epitopes is critical, as only antibodies against the intact capsid structure can effectively neutralize the virus in vivo (Christensen et al., 1996, J Virol).
Vaccine-derived virus-like particles (VLPs) act as ligands that bind to and cross-link the B-cell receptors (BCRs) on naïve B cells, initiating signal transduction through the Ig-alpha/Ig-beta heterodimer that leads to B-cell activation, proliferation, and differentiation into long-lived plasma cells and memory B cells (Schiller & Lowy, 2012, Nat Rev Microbiol).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Naïve B-cell receptor specific for Human Papillomavirus L1 conformational epitopes (HPV L1-specific BCR).